Bioinformatics &

Digital Health

Bioinformatics and Digital Health encompass many different fields of application. Continued advancements in bioinformatics are driving forward key developments in precision medicine, placing the patient at the heart of decisions.

We work with innovators in sequencing, genomics, proteomics, metabolomics and cell biology, as well as biosensors and artificial intelligence. We understand the challenges in this area, and can advise you on how to adapt your IP strategy to deal with these.

Our core bioinformatics team includes attorneys whose practice has a strong focus in this field, with backgrounds in bioinformatics/computational biology, biochemistry, electronics, physics and engineering. They form part of a wider multi-disciplinary team that is over 20-strong and made up of scientists and engineers who have deep knowledge and understanding of the variety of technologies and fields that bioinformatics touches.

We have our finger on the pulse of developments in EPO practice in relation to bioinformatics inventions. We have an impressive record of getting seemingly difficult cases through to grant. 

Digital Health innovations can give rise to a number of valuable assets from data to code, designs of user interfaces, new methods and know-how, each of which can be associated with multiple individual IP rights, both registered and unregistered. Our highly skilled legal team works seamlessly alongside our patent experts to help our clients build a strong bundle of IP rights, including copyrights, trade secrets, database rights, designs and patents. Our integrated team approach means that we can be with you all the way and across the whole spectrum of your IP needs, ensuring efficient, joined-up and commercially relevant advice.

Find out more on our Bioinformatics spotlight page.

Patent_Landscape_in_Bioinformatics_and_Digital_Health_Special_Report_2021-2-Compressed

Special Report

Patent Landscape in Bioinformatics and Digital Health: a data-driven analysis

The words "digital health", "data driven" and "AI" have been on everyone's lips and in many headlines in the healthcare and life sciences sectors over the last couple of years. However, navigating this rapidly changing landscape can be challenging for those in charge of managing the IP associated with the innovations underpinning these changes.  

In this Special Report, we set out to collect data on the patent landscape in the fields of bioinformatics and digital health, to see whether the growth we and our clients see in the field is reflected in the data and whether insights can be gained from the data that will assist in designing better, more informed IP strategies.

Read our blogs

UPC Weekly - Language of proceedings at the UPC

UPC Weekly - Language of proceedings at the UPC

2024 Week 16 This week we focus on the language of proceedings at the UPC, considering when the defendant can successfully request a change of the language of proceedings, and an overview of the ...

UPC Weekly - Time-dependent transparency of UPC proceedings?

UPC Weekly - Time-dependent transparency of UPC proceedings?

2024 Week 15 The week saw the Court of Appeal issue its decision on public access to court file documents in the Ocado v. Autostore case. We set out the background to the issues in a previous blog. A ...

UPC Weekly - Mind your costs

UPC Weekly - Mind your costs

2024 Week 14 The UPC Court of Appeal issued a collection of five appeal decisions on 3 April 2024 in the ongoing litigation between NJOY and Juul relating to vaping products. The substance of the ...

Public access to UPC proceedings

Public access to UPC proceedings

When the UPC was set up, a basic tenet was set out in Article 45 of the UPC Agreement, that the court proceedings would be public. This was intended not only to apply to trials, but also to the ...

Efficiency in Expansion: Meeting the Scale-Up Challenge in Cell and Gene Therapies

Efficiency in Expansion: Meeting the Scale-Up Challenge in Cell and Gene Therapies

One of the pivotal challenges in the development and commercialisation of cell and gene therapies lies in scaling-up production. This challenge is particularly pronounced as companies transition from ...

EPO related support measures for small entities – 1 April 2024

EPO related support measures for small entities – 1 April 2024

INTRODUCTION From 1 April 2024, the EPO are introducing a new fee reduction scheme specifically for micro-entities. This initiative, in addition to the existing language-related fee reductions, aims ...

Forward Magazines Overlapping 6-compressed

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.